Hunter Gillies - 07 Feb 2023 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Role
CHIEF MEDICAL OFFICER
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Issuer symbol
JBIO
Transactions as of
07 Feb 2023
Net transactions value
$0
Form type
4
Filing time
08 Feb 2023, 17:10:12 UTC
Previous filing
16 Dec 2021
Next filing
25 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AVTE Common Stock 1,960 07 Feb 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Award $0 +62,000 $0.000000 62,000 07 Feb 2023 Common Stock 62,000 $25.57 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,960 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on October 31, 2022 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d).
F2 This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on March 7, 2023.